Extended-schedule dose-dense temozolomide in refractory gliomas

Journal of Neuro-Oncology

Volumn 96, Issue 3, 2010, Pages 417-422

  Berrocal, A ^a   Perez Segura, P ^b   Gil, M ^c   Balana C ^d   Garcia Lopez, J ^e   Yaya, R ^f   Rodriguez J ^g   Reynes, G ^h   Gallego, O ⁱ   Iglesias, L ^j  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^g Hospital de Sondureta   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

Activity; Malignant glioma; Refractory; Temozolomide

Indexed keywords

CARMUSTINE; CISPLATIN; CORTICOSTEROID; ETIRACETAM; GABAPENTIN; LOMUSTINE; METOCLOPRAMIDE; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER GRADING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEIZURE; SPAIN; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75049085445     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9980-7     Document Type: Article

References (28)

1. MR Gilbert 2006 Advances in the treatment of primary brain tumors: dawn of a new era? Curr Oncol Rep 8 45 49 10.1007/s11912-006-0008-6 16464402
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009 (Pubitemid 40349501)
3. WK Yung RE Albright J Olson, et al. 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593 10.1054/bjoc.2000.1316 1:CAS:528:DC%2BD3cXmvVCgsrs%3D 10944597
4. ES Newlands MF Stevens SR Wedge RT Wheelhouse C Brock 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35 61 10.1016/S0305-7372(97)90019-0 1:CAS:528:DyaK2sXktFOrt7w%3D 9189180 (Pubitemid 27273454)
5. MJ Tisdale 1987 Antitumor imidazotetrazines-XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones Biochem Pharmacol 36 457 462 10.1016/0006-2952(87)90351-0 1:CAS:528:DyaL2sXhs1ynurc%3D 3470008 (Pubitemid 17024167)
6. AE Pegg 2000 Repair of O(6)-alkylguanine by alkyltransferases Mutat Res 462 83 100 10.1016/S1383-5742(00)00017-X 1:CAS:528:DC%2BD3cXisVKgsbs%3D 10767620 (Pubitemid 30190216)
7. MS Bobola SH Tseng A Blank MS Berger JR Silber 1996 Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin Clin Cancer Res 2 735 741 1:CAS:528:DyaK28Xis1Wluro%3D 9816224
8. ME Hegi A-C Diserens T Gorlia, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D 15758010 (Pubitemid 40349502)
9. SM Lee N Thatcher D Crowther GP Margison 1994 Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide Br J Cancer 69 452 456 1:CAS:528:DyaK2cXlsVynsLw%3D 8123472
10. AW Tolcher SL Gerson L Denis, et al. 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 1004 1011 10.1038/sj.bjc.6600827 1:CAS:528: DC%2BD3sXisFahtrY%3D 12671695 (Pubitemid 36560766)
11. JC Baer AA Freeman ES Newlands AJ Watson JA Rafferty GP Margison 1993 Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells Br J Cancer 67 1299 1302 1:CAS:528:DyaK3sXlvFGht7g%3D 8512814
12. L Denis A Tolcher JA Figueroa, et al. 2000 Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic- pharmacodynamic study (abstract) Proc Am Soc Clin Oncol 19 202a Abstract 786
13. R Simon 1987 How large should a phase II trial of a new drug be? Cancer Treat Rep 71 1079 1085 1:STN:280:DyaL1c%2Flt1OjsQ%3D%3D 3315196
14. DR Macdonald TL Cascino SC Schold JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
15. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) (published correction appears in J Clin Oncol 2005;23(1):248). J Clin Oncol 22:4779-4786
16. VK Puduvalli P Giglio MD Groves, et al. 2008 Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro Oncol 10 216 222 10.1215/15228517-2007-060 1:CAS:528:DC%2BD1cXls1Gjsb4%3D 18314417
17. DA Reardon JA Quinn JN Rich, et al. 2004 Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma Neuro Oncol 6 134 144 10.1215/S1152851703000413 1:CAS:528:DC%2BD2cXjs1Sqtbo%3D 15134628 (Pubitemid 38455760)
18. MA Rosenthal DL Ashley L Cher 2004 BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide J Clin Neurosci 11 374 375 10.1016/j.jocn.2003.01.002 1:CAS:528:DC%2BD2cXjtVensrw%3D 15080950 (Pubitemid 38568473)
19. JJ Vredenburgh A Desjardins JE Herndon II, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 10.1200/JCO.2007.12.2440 1:CAS:528:DC%2BD2sXhtlCgsLjF 17947719 (Pubitemid 350086473)
20. Perry JR, Mason WP, Belanger K et al (2008) The temozolomide RESCUE study: a phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma (abstract). J Clin Oncol 26(Suppl):91s (abstract 2010)
21. Wick A, Pascher C, Wick W et al (2009, Epub ahead of print) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol
22. E Franceschi AM Omuro AB Lassman A Demopoulos C Nolan LE Abrey 2005 Salvage temozolomide for prior temozolomide responders Cancer 104 2473 2476 10.1002/cncr.21564 1:CAS:528:DC%2BD2MXhtlWgt7bF 16270316 (Pubitemid 41691570)
23. A Wick J Felsberg JP Steinbach, et al. 2007 Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma J Clin Oncol 25 3357 3361 10.1200/JCO.2007.10.7722 1:CAS:528:DC%2BD2sXhtVWqs7nO 17664483 (Pubitemid 47325623)
24. CS Brock ES Newlands SR Wedge, et al. 1998 Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res 58 4363 4367 1:CAS:528:DyaK1cXmsVyqsbg%3D 9766665
25. AA Brandes A Tosoni G Cavallo, et al. 2006 Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 1155 1160 10.1038/sj.bjc.6603376 1:CAS:528:DC%2BD28XhtFChs73O 17024124 (Pubitemid 44658477)
26. W Wick M Weller 2005 How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience J Clin Oncol 23 4235 4236 10.1200/JCO.2004.00.8417 15961774 (Pubitemid 46211332)
27. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 1470 1475 10.1200/JCO.2006.07.4807 1:CAS:528:DC%2BD2sXlsVyntbo%3D 17442989 (Pubitemid 46733073)
28. B Neyns C Chaskis E Joosens, et al. 2008 A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma Cancer Invest 26 269 277 10.1080/07357900701708393 1:CAS:528:DC%2BD1cXislalsrk%3D 18317968 (Pubitemid 351329006)